ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) complied with federal securities laws. On October 12, 2023, Science reported that, following an investigation, the City University of New York ("CUNY") accused "a CUNY faculty member and longtime Cassava collaborator, of scientific misconduct involving 20 research papers," many of which provided support for the development and use in clinical studies of Cassava's drug, simufilam. The CUNY investigation also concluded that Cassava's senior ...
SAVA) Announced by Holzer & Holzer, LLC>Full story available on Benzinga.com